(3R,4R)-4-methoxy-3-methylpiperidine | 1421253-13-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (3R,4R)-4-methoxy-3-methylpiperidine
• CAS: 1421253-13-5
• 化学式: C₇H₁₅NO
• 分子量: 129.202
• InChiKey: IANZRNIJJWLDGA-RNFRBKRXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (3S,4S)-4-methoxy-3-methylpiperidine 、 (3R,4R)-3-methylpiperidin-4-yl pivalate 生成 (3R,4R)-4-methoxy-3-methylpiperidine
  参考文献：
  名称：

  TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS

  摘要：

  本发明提供一个公式I的化合物：一种制造本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂的组合和一种制药组合物。

  公开号：

  US20140349995A1

文献信息

• [EN] INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)<br/>[FR] INHIBITEURS DE LA KINASE CYCLINE-DÉPENDANTE 7 (CDK7)
  申请人：SYROS PHARMACEUTICALS INC

  公开号：WO2019143719A1

  公开（公告）日：2019-07-25

  The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).

  本发明提供了具有此处描述的结构的化合物；其药学上可接受的盐、溶剂化合物、水合物、互变体以及同位素形式；以及含有上述化合物和/或药学组合物的组合物（例如，药物组合物和试剂盒）。还提供了涉及上述化合物和/或药学组合物用于治疗或预防疾病的给药方法和用途。该疾病可以是增生性疾病，例如癌症（例如，血液癌症（例如，白血病或淋巴瘤），脑癌，乳腺癌，黑色素瘤，多发性骨髓瘤或卵巢癌），良性肿瘤，病理性血管生成，或纤维化疾病。尽管该发明的任何方面都不受可能发生的生物事件的限制，但给予此处描述的化合物或其他组合物可能选择性地抑制细胞周期依赖性激酶7（CDK7）的异常表达或活性，并因此在患者（或生物样本）中诱导细胞凋亡和/或抑制与疾病相关基因的转录。
• [EN] 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL]INDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DÉRIVÉS DE 5-[5-(PIPERIDIN-4-YL)THIENO[3,2-C]PYRAZOL-2-YL] ET COMPOSÉS ASSOCIÉS UTILISÉS COMME MODULATEURS POUR L'ÉPISSAGE DES ACIDES NUCÉIQUES ET POUR LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：REMIX THERAPEUTICS INC

  公开号：WO2022006543A1

  公开（公告）日：2022-01-06

  The present disclosure features compounds e.g. of formula (I-a) and similar compounds e.g. of formulae (l-g), (l-i), (l-j), (III), (lll-a), (III- b) and (IV) disclosed herein and other related compounds, and pharmaceutical compositions thereof. The present disclosure further discloses said compounds and their compositions for use in methods of modulating nucleic acid splicing, as well as said compounds for use in methods of treating e.g.: • proliferative diseases, such as e.g. cancer, benign neoplasms or angiogenesis, • neurological diseases or disorders, such as e.g. Huntington's disease, • autoimmune diseases or disorders, immunodeficiency diseases or disorders, lysosomal storage disease or disorder, cardiovascular diseases or disorders, metabolic diseases or disorders, respiratory diseases or disorders, renal diseases or disorders, or infectious diseases. Exemplary compounds are e.g. 5-[5-(piperidin-4-y l)thieno[3,2- c]pyrazol-2-yl]indazole and 5-[2-(piperidin-4-yl)-[1,2,4]triazolo[3,2-b] [1,3]thiazol-5-yl]indazole derivatives and related compounds.

  本公开涉及化合物，例如式(I-a)的化合物以及类似的化合物，例如式(l-g)，(l-i)，(l-j)，(III)，(lll-a)，(III-b)和(IV)以及其他相关化合物及其药物组合物。本公开进一步揭示了所述化合物及其组合物用于调节核酸剪接的方法，以及所述化合物用于治疗的方法，例如： •增殖性疾病，例如癌症、良性肿瘤或血管生成， •神经疾病或障碍，例如亨廷顿病， •自身免疫疾病或障碍，免疫缺陷疾病或障碍，溶酶体贮积病或障碍，心血管疾病或障碍，代谢性疾病或障碍，呼吸系统疾病或障碍，肾脏疾病或障碍，或传染病。示例化合物包括例如5-[5-(哌啶-4-基)噻吩[3,2-c]吡唑-2-基]吲唑和5-[2-(哌啶-4-基)-[1,2,4]三唑噻吩[3,2-b][1,3]噻唑-5-基]吲唑衍生物及相关化合物。
• Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
  申请人：Adams Christopher Michael

  公开号：US08846656B2

  公开（公告）日：2014-09-30

  The present invention provides a compound of formula I: (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了I式化合物：(I)的配方，以及制造该发明化合物的方法和其治疗用途。本发明还提供了药理活性剂的组合和制药组合物。
• CYCLIN-DEPENDENT KINASE INHIBITORS
  申请人：SPV THERAPEUTICS INC.

  公开号：US20220056037A1

  公开（公告）日：2022-02-24

  Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.
• US8846656B2
  申请人：——

  公开号：US8846656B2

  公开（公告）日：2014-09-30